Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $39,474.00 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval sold 11,610 shares of the company’s stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $39,474.00. Following the completion of the transaction, the director now directly owns 75,390 shares of the company’s stock, valued at approximately $256,326. The trade was a 13.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Puma Biotechnology Price Performance

PBYI opened at $3.40 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53. Puma Biotechnology, Inc. has a 1-year low of $2.23 and a 1-year high of $4.13. The company has a 50-day moving average of $3.22 and a 200-day moving average of $3.12. The company has a market capitalization of $168.74 million, a P/E ratio of 4.42 and a beta of 1.29.

Institutional Trading of Puma Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in Puma Biotechnology by 19.5% during the 4th quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company’s stock worth $1,012,000 after buying an additional 54,150 shares during the last quarter. Los Angeles Capital Management LLC raised its position in shares of Puma Biotechnology by 16.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 285,679 shares of the biopharmaceutical company’s stock valued at $871,000 after acquiring an additional 39,984 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Puma Biotechnology by 32.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 487,368 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 118,913 shares during the last quarter. American Century Companies Inc. lifted its stake in Puma Biotechnology by 8.4% during the fourth quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company’s stock worth $2,893,000 after purchasing an additional 73,833 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in Puma Biotechnology by 8.0% in the fourth quarter. Sei Investments Co. now owns 311,661 shares of the biopharmaceutical company’s stock worth $951,000 after purchasing an additional 23,179 shares during the period. 61.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on PBYI. Wall Street Zen raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 22nd. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.